Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Vascul Pharmacol. 2015 Jul 26;76:42–52. doi: 10.1016/j.vph.2015.07.011

Figure 1.

Figure 1

Human coronary artery endothelial cells (HCAECs) were maintained in endothelial basal medium (EBM-2) alone (Control) or EBM-2 containing thapsigargin (“Thaps”, 1 μM) or tunicamycin (“Tun”, 10 μg/ml) for 24 hours in the presence or absence of the non-selective channel blocker SKF96,365 (“SKF”, 30 μM), and then processed for in vitro TUNEL assay. Treatment with SKF alone was included as a control. P values for the differences between treatments with and without SKF are shown. Differences between treatments with thapsigargin or tunicamycin and the control had P <0.0001. All values are mean ± SEM (n=3–5).